Success Metrics

Clinical Success Rate
100.0%

Based on 8 completed trials

Completion Rate
100%(8/8)
Active Trials
2(18%)
Results Posted
13%(1 trials)

Phase Distribution

Ph phase_1
9
82%
Ph phase_3
2
18%

Phase Distribution

9

Early Stage

0

Mid Stage

2

Late Stage

Phase Distribution11 total trials
Phase 1Safety & dosage
9(81.8%)
Phase 3Large-scale testing
2(18.2%)

Highest Phase Reached

Phase 3

Trial Status & Enrollment

Completion Rate

100.0%

8 of 8 finished

Non-Completion Rate

0.0%

0 ended early

Currently Active

2

trials recruiting

Total Trials

11

all time

Status Distribution
Active(3)
Completed(8)

Detailed Status

Completed8
Not yet recruiting1
Recruiting1
Active, not recruiting1

Development Timeline

Analytics

Development Status

Total Trials
11
Active
2
Success Rate
100.0%
Most Advanced
Phase 3

Trials by Phase

Phase 19 (81.8%)
Phase 32 (18.2%)

Trials by Status

not_yet_recruiting19%
recruiting19%
active_not_recruiting19%
completed873%

Recent Activity

2 active trials
Showing 5 of 11
recruitingphase_3

A Clinical Study of Enlicitide in Participants With High Cholesterol (MK-0616-037)

NCT07216482
completedphase_3

A Study to Evaluate the Efficacy and Safety of Enlicitide (MK-0616, Oral PCSK9 Inhibitor) Compared With Ezetimibe or Bempedoic Acid or Ezetimibe and Bempedoic Acid in Adults With Hypercholesterolemia (MK-0616-018/CORALreef AddOn)

NCT06450366
not_yet_recruitingphase_1

A Clinical Study of the Effect of Enlicitide (MK-0616) Formulations in Healthy Participants (MK-0616-041)

NCT07481708
active_not_recruitingphase_1

A Clinical Trial of Enlicitide and Rosuvastatin in Healthy Adults (MK-0616-039)

NCT07300280
completedphase_1

A Clinical Study of How Coffee and Tea Affect Enlicitide in Healthy Volunteers (MK-0616-040)

NCT07044479
View all 11 trials

Clinical Trials (11)

Showing 11 of 11 trials
NCT07216482Phase 3

A Clinical Study of Enlicitide in Participants With High Cholesterol (MK-0616-037)

Recruiting
NCT06450366Phase 3

A Study to Evaluate the Efficacy and Safety of Enlicitide (MK-0616, Oral PCSK9 Inhibitor) Compared With Ezetimibe or Bempedoic Acid or Ezetimibe and Bempedoic Acid in Adults With Hypercholesterolemia (MK-0616-018/CORALreef AddOn)

Completed
NCT07481708Phase 1

A Clinical Study of the Effect of Enlicitide (MK-0616) Formulations in Healthy Participants (MK-0616-041)

Not Yet Recruiting
NCT07300280Phase 1

A Clinical Trial of Enlicitide and Rosuvastatin in Healthy Adults (MK-0616-039)

Active Not Recruiting
NCT07044479Phase 1

A Clinical Study of How Coffee and Tea Affect Enlicitide in Healthy Volunteers (MK-0616-040)

Completed
NCT06643377Phase 1

A Clinical Study of Enlicitide in Participants With Severe Renal Impairment (MK-0616-032)

Completed
NCT06880874Phase 1

A Clinical Study to Evaluate Enlicitide (MK-0616) Formulations in Healthy Adult Participants (MK-0616-035)

Completed
NCT06575959Phase 1

A Clinical Study of Enlicitide Decanoate in People With Liver Function Problems (MK-0616-030)

Completed
NCT06719544Phase 1

A Study of Lithium and Enlicitide in Healthy Adult Participants (MK-0616-034)

Completed
NCT06609512Phase 1

A Clinical Study of Enlicitide and the Effect of Food in Healthy Adult Participants (MK-0616-033)

Completed
NCT06597760Phase 1

A Clinical Study to Assess the Effect of Enlicitide on How the Body Processes Digoxin in Healthy Adult Participants (MK-0616-031)

Completed

All 11 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
11